Candriam S.C.A. Has $20.47 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

Candriam S.C.A. boosted its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 12.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 614,671 shares of the biotechnology company's stock after acquiring an additional 66,552 shares during the period. Candriam S.C.A. owned approximately 0.22% of Exelixis worth $20,469,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Stephens Inc. AR bought a new position in shares of Exelixis during the 3rd quarter worth about $251,000. Farther Finance Advisors LLC grew its position in Exelixis by 467.7% in the third quarter. Farther Finance Advisors LLC now owns 3,940 shares of the biotechnology company's stock valued at $102,000 after acquiring an additional 3,246 shares during the period. Van ECK Associates Corp grew its position in Exelixis by 66.2% in the third quarter. Van ECK Associates Corp now owns 173,584 shares of the biotechnology company's stock valued at $4,916,000 after acquiring an additional 69,134 shares during the period. Robeco Institutional Asset Management B.V. raised its stake in Exelixis by 263.1% during the third quarter. Robeco Institutional Asset Management B.V. now owns 483,064 shares of the biotechnology company's stock worth $12,536,000 after acquiring an additional 350,026 shares in the last quarter. Finally, QRG Capital Management Inc. lifted its holdings in shares of Exelixis by 6.4% during the third quarter. QRG Capital Management Inc. now owns 54,879 shares of the biotechnology company's stock valued at $1,424,000 after acquiring an additional 3,321 shares during the period. Institutional investors and hedge funds own 85.27% of the company's stock.

Remove Ads

Insider Buying and Selling at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 10,000 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $38.80, for a total value of $388,000.00. Following the completion of the sale, the executive vice president now owns 341,028 shares of the company's stock, valued at approximately $13,231,886.40. This represents a 2.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Christopher J. Senner sold 29,314 shares of Exelixis stock in a transaction on Monday, February 24th. The stock was sold at an average price of $36.14, for a total transaction of $1,059,407.96. Following the transaction, the chief financial officer now directly owns 779,607 shares in the company, valued at approximately $28,174,996.98. This represents a 3.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 140,343 shares of company stock valued at $5,177,234. 2.85% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Barclays upped their target price on shares of Exelixis from $25.00 to $29.00 and gave the stock an "equal weight" rating in a report on Thursday, February 13th. Brookline Capital Management started coverage on shares of Exelixis in a report on Monday, December 23rd. They set a "buy" rating for the company. Piper Sandler boosted their target price on Exelixis from $37.00 to $38.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. Truist Financial raised their price target on Exelixis from $42.00 to $43.00 and gave the company a "buy" rating in a report on Monday, January 27th. Finally, HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Exelixis in a research report on Thursday, February 13th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Exelixis has a consensus rating of "Moderate Buy" and a consensus target price of $37.24.

Exelixis Trading Up 1.5 %

Shares of EXEL traded up $0.57 on Monday, reaching $39.15. 3,877,677 shares of the company's stock were exchanged, compared to its average volume of 2,080,963. The business has a 50 day moving average price of $34.99 and a two-hundred day moving average price of $32.12. Exelixis, Inc. has a 12 month low of $20.14 and a 12 month high of $40.00. The stock has a market capitalization of $10.96 billion, a P/E ratio of 22.12, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Equities research analysts predict that Exelixis, Inc. will post 2.04 EPS for the current year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.